Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells

(2009) Paolo Salerno et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling

(2009) D. A. Ritt et al.   MOLECULAR AND CELLULAR BIOLOGY

Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis

(2009) K. Boisvert-Adamo et al.   MOLECULAR CANCER RESEARCH

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report

(2009) Vernon K. Sondak et al.   Pigment Cell & Melanoma Research

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant B-RAF mediates resistance to anoikis via Bad and Bim

(2008) K Boisvert-Adamo et al.   ONCOGENE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA